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Abstract
MITOCHONDRIAL GENE EXPRESSION IN HUMAN
MONONUCLEAR CELLS
By Monika D. Ruchała, M.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2014.
Director: Dr. James P. Bennett Jr, M.D., Ph.D., Bemiss Professor
Departments of Neurology, Psychiatry and Physiology and Biophysics
Adult neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS), have
been intensively studied in recent years in pursuit of mechanisms responsible for origin
and progression. One emerging theme is mitochondrial energetic deficiency as a
mechanism of neuronal death. Recent descriptions of protocols to generate induced
pluripotent stems cells (iPSCs) from living patients offer the potential to create unique
disease models. This model can potentially lead to crucial advances in developing
treatment options for a wide variety of neurodegenerative diseases. In this thesis, we
attempt to induce iPSCs from mononuclear cells (MNC) in peripheral blood acquired
from patients with ALS and healthy control (CTL) subjects, and analyze their
mitochondrial genomes. The reprogramming of MNC to yield iPSC was done by
nucleofection of an episomal plasmid pEB- C5, expressing OriP sequences of the
EpsteinBarr and five reprogramming transgenes Oct4, Sox2, Klf4, c-Myc and Lin28. We
investigated the expression of mitochondrial DNA genes, ND2, ND4, COXIII and 12s
rRNA in the ALS and CTL MNC before and after their culturing. The results implicate
deregulated mitochondrial bioenergetics as a characteristic of ALS. Future work will

establish whether these abnormalities in mitochondrial bioenergetics persist in iPSC’s
and iPSC-derived neurons from ALS subject

Chapter 1:
1.1 Amyotrophic Lateral Sclerosis (ALS)
Neurodegeneration is a debilitating process in which nerve cells slowly lose their
functionality and/or die over many years, producing clinical manifestations of
neurodegenerative diseases. These widespread diseases of the nervous system affect
humans in different ways and produce symptoms both within the brain and in different
somatic tissues, impeding their proper functioning. Common neurodegenerative diseases
include Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and Amyotrophic
lateral sclerosis (ALS). The origins of these diseases are thought to be multi-factorial,
genetic, as well as environmental.

Jean Martin Charcot first described “Lou Gehrig’s Disease,” the eponym created in the
US in honor of a Yankee baseball player diagnosed with ALS at age 39, in 1869 as a
motor neuron disease (Charcot and Joffroy, 1869). He observed an abnormal appearance
of white matter and reactive astrocytes and microglia in lateral corticospinal tracks. This
myelin pallor (pallere -be pale in Latin, lack of color and sickliness) and gliosis (reactive
response to damage) indicated degeneration of axons of upper motor neurons descending
from the brain’s precentral gyrus (primary motor cortex) to the spinal cord. Originally
named Charcot’s sclerosis, the disease was eventually named amyotrophic lateral
sclerosis as the axonopathy of the upper motor neurons was associated with degeneration
of lower motor neurons in the spinal cord and manifested in the atrophy of muscles
(Boillee et al., 2006; Nelson, 2003). In Europe, ALS is called motor neuron disease,
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which unambiguously conveys an explanation of the source of muscle weakness that is
motor neuron degeneration (Nelson, 2003).

The lifetime risk for ALS has been estimated as 1 in 1000, with 1-2 per 100000 of new
cases per year and 4-6 per 100000 of affected individuals (Boillee et al., 2006). That
translates, according to the ALS Association, to approximately 5,600 people in the U.S.
diagnosed with ALS each year, and 30,000 Americans having the disease at any given
time. Typically the disease affects middle-aged people (40-60 years old) but it can also
strike at the younger age. Currently, there is no cure for ALS. It has been reported that
50% of the deaths occur within three years from the disease onset (Saris et al., 2009;
Dupuis et al., 2011; Boillee et al., 2006). The most common form of ALS is sporadic,
which have been thought to account for 90% of all ALS cases (Saris et al., 2009; Dupuis
et al., 2011;Boillee et al, 2006). However, a recent Medline literature review and meta
analysis of previously reported data, indicated that the familial form of ALS accounts for
only 5.1 % (not 10 %) of all ALS cases, with even lower rate in Southern Europe. This
discrepancy have been attributed to the fact there was a preferential recruitment of
familial ALS patients, and that there is no clear definition of relatedness with only two
members of extended family to be considered related (Byrne et al., 2014). Most ALS
cases thus occur sporadically ~95% of the time.

The first manifestation of ALS differs between individuals. Some patients experience
muscle weakness and cramping in hands, arms or legs. Others have difficulty speaking
and projecting their voice as a result of facial muscle weakness. The disease progresses to
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speech impairment and spasticity, and at more advanced stages to muscle atrophy,
shortness of breath and consequently to paralysis of respiratory muscles and death. ALS
not only affects the nervous system but also other body tissues as shown by genome wide
studies of sporadic ALS (Dupuis et al., 2011).

As a consequence of the multivariate onset and presentation of ALS, it is sometimes
called a syndrome rather than the nosological disease entity. The multifaceted and
versatile presentation of ALS challenges its diagnosis. Clinicians perform meticulous
neurological examinations and tests to exclude other neurological diseases, rather than
identify ALS by looking solely at its symptoms. Some of these tests include
electromyography (EMG), nerve conduction velocity (NCV), high-resolution serum
protein electrophoresis, lumbar puncture, myelograms (now MRI scans) of cervical spine
and muscle and/or nerve biopsy.
Mutations in many different genes are associated with Familial ALS (FALS)
Studies of familial forms of ALS (FALS) indicate that this autosomally dominant disease
is associated with the mutations of genes located on at least six different chromosomes.
Mutations leading to typical ALS, with a late-onset, progressive deterioration of upper
and lower motor neurons are located on chromosomes 21, 18, 16, and 20 at the loci called
ALS1, ALS3, ALS6 and ALS7 respectively.

The only gene identified for the clinically typical ALS is the one that encodes
Copper/Zinc Super Oxide Dismutase (Cu/Zn SOD1), which converts (“dismutates”)
superoxide to hydrogen peroxide and is localized mainly to cytosol. It is located on
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chromosome 21 at the locus ALS1 (Dupuis et al. 2011; Boillee et al. 2006; Nelson,
2003).

Out of two forms of ALS with dementia, frontal temporal dementia (FTD) and FTD with
Parkinson’s disease (FTDPD), only the locus called ALS-FTD has been successfully
related to a gene (MAPT), which is a microtubule-associated protein. This locus is
located on chromosome 17 and ALS-FTD locus is located on chromosome 9. An
atypical, heterogeneous form of ALS, manifested by unusual tremor, is caused by a
mutation in vesicle associated membrane protein B (VAMB) gene that is located on
chromosome 20 at the locus called ALS8. The gene product is involved in a vesicular
transport from endoplasmic reticulum to Golgi apparatus and transport of cargo to
membrane in an axon. Another atypical form of ALS related to a mutation on
chromosome 2 at the locus associated with progressive lower motor neuron disease. The
gene found at this locus, DCTN1, codes for a dydactin subunit, which is a part of axonal
transport. The onset of this form of ALS is observed in adults and leads to vocal-cord
paralysis.

The names of the loci ALS2, ALS4, and ALS5 located on chromosomes 2, 9 and 15
respectively, are in some way misnomers because those mutations are associated with
juvenile forms of motor neuron diseases, not ALS (Rosen et al., 1993; Hand et al., 2002;
Chen et al., 2004; Hadano et al., 2001; Nishimura et al., 2004; Boillee et al., 2006).
Numbers of studies have also identified genes that promote ALS progression. According
to gene analysis of human postmortem sensory and motor cortexes, ALS subjects showed
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differential expressions of 275 genes (Wang et al., 2006). Ten of those genes were
upregulated; six associated with surface activity and two with glutamate receptors
(consistent with excitoxicity of glutamate). The remaining, down-regulated more than
four fold genes were: zinc finger protein 36, C3H type-like 1, inhibitor of DNA binding
4, and heterogeneous nuclear ribonucleoprotein H1 (group of genes were involved in
transcription), ribosomal protein S11, (protein/amino acid synthesis and turnover group)
nuclear receptor subfamily 4, group A, member 3, and inhibin, beta C
(neurotransmission, hormones group), vascular endothelial growth factor (survival and
growth), small protein effector 1 of Cdc42 (signaling), dynein 2 light intermediate chain
(cytoskeletal tubulin and cell adhesion molecule), transducer of ERBB2, 1
(differentiation or proliferation ), protein regulated in glioma and forming binding protein
3 (growth factor receptor-bound protein) (Wang et al., 2006).

A decrease in vascular endothelial growth factor (VEGF) as a consequence of a mutation
in a promoter region of VEGF gene has been linked to increased risk of ALS in Belgium,
Sweden, and Britain (Lambrechts et al., 2003; Gros-Louis et al., 2003). This growth
factor is essential in angiogenesis not only the developmental, but also hypoxia-induced
(Wang, 2006.) Angiogenesis can be also negatively affected by a mutation in angenin
gene ANG, mainly in the core subunit (Boillee et al., 2006; Greenway et al., 2006).

Neurofilament’s mutations may be also a risk factor for ALS although there is no
conclusive linkage between the disease and the NF aggregates observed in familial and
sporadic ALS patients (Garcia et al., 2006). Other down-regulated genes were involved in
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ubiquitin- proteasome function, apoptosis, lipid metabolism, inflammation, oxidative
stress and energy metabolism. Specifically, down regulated genes related to
mitochondrial energy metabolism included: methionine adenosyltransferase II alpha,
myotubularin related protein, thioredoxin, and CD24 antigen (small cell lung carcinoma
cluster 4 antigen) (Wang et al., 2006).

Energy deregulation plays a central role in ALS progression. In a healthy person intake of
energy in form of food and production of energy normally equilibrates energy
expenditure. An overeating, static life style leads to insulin resistance, which results in a
decreased energy delivered to cells as in diabetes mellitus type 2. On the other hand
raised oxygen consumption, decreased food intake or mitochondrial dysfunction lead to
weight loss and malnutrition. In ALS patients, for reasons currently unknown, the energy
balance is interrupted by hypermetabolism, which precedes denervation. Studies of
sporadic ALS of genes responsible for metabolism led to no conclusive results. What is
also baffling is that ALS patients experience hyper lipidemia with increased LDL/HDL
ratio (Dupouis et al., 2011).
Does study of motorneuron groups help us understand their vulnerability in ALS?
To understand selective vulnerability to degeneration of motor neurons in different areas
of the nervous system in different neurodegenerative diseases, neurons of rats were
isolated by laser capture microdissection and following areas were analyzed:
oculomotor/trochlear (cranial nerve 3/4, unaffected in ALS), hypoglossal (cranial nerve
12, affected in ALS) and lateral motor column of the cervical spinal cord (highly affected
in ALS). Analyzed gene expression of these regions revealed that all regions exhibited
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unique gene expression profiles; however, there was some similarity in CN12 and lateral
spinal column gene expression. All of the regions had differential expression of Hox
genes, mitochondrial functions, ubiquitination, apoptosis regulation, nitrogen
metabolism, calcium regulation, transport, and RNA processing genes (Hedlung et al,
2010). This is consistent with observations of aggregates caused by mutations in the
genes of ubiquitin, TAR DNA binding protein of 43-kDa (TDP-43), and fused sarcoma
protein (FUS) in ALS mouse models (Kwiatkowski et al., 2009; Dupuis et al., 2011).
These studies did not reveal any selective properties of ALS-vulnerable neuron
populations compared to those that typically do not degenerate in ALS.
SOD1 mutations can cause Familial ALS (FALS)
Out of all genetically inherited forms of ALS, it has been previously reported that
mutation in SOD1 accounts for 10-20% of FALS cases (Boillee et al., 2006; Wang et al.,
2006). Specifically, mutation of alanine to valine-SODA4V elicits the most aggressive
form of ALS and is the most prevalent one in the US (50%) (Boillee et al., 2006).
However, according to the only population based study that was conveyed in Italy, the
SOD1 mutation accounted for only 13.6% of FALS (Chio et al., 2008; Byrne et al.,
2014).
The gene product of SOD1 gene is 153 amino acids long and it is mainly cytosolic, but
some appears to be mitochondrial. Its function is to detoxify superoxide anion by
converting it to hydrogen peroxide that is ultimately detoxified to water. It had been
therefore postulated that the loss of this dismutase function might be associated with ALS
phenotype. However this did not seem to be the case because in a course of different
research undertakings, it was shown that active and inactive enzyme result in similar

7

disease presentation (Fischer et al., 2004; Frey et al., 2000; Pun et al., 2006) Moreover,
the deletion of the enzyme in mice does not produce an ALS phenotype (Reaume et al.,
1996). SOD1 requires Cu and Zn for proper functioning. Copper, toxic if free in the cell,
loaded into SOD1 aids the oxidative process. A study of mice with eliminated copper
showed however no difference in ALS phenotype (Subramaniam et al., 2002; Boillee et
al.2006; Wang et al., 2006). On the other hand it has been shown in SOD1 mutant mice
that zinc deficiency can accelerate the disease manifestation and in that situation
mitochondrial SOD1 generates more free radicals (Wang et al., 2006).
In a search for an explanation of unknown source of toxicity of SOD1 mutation it
has been proposed that it might be a result of a defective protein folding. This could
explain aggregations of SOD1, which are one of the trademarks of ALS (Wang et al.,
2003). These SOD1 aggregates bind to many cellular components negatively affecting
their function. Among some of them are proteasomes, in which SOD1 aggregate binding
leads to abnormal protein degradation, and chaperones, which lead to impaired protein
folding. Moreover, mutant SOD1 that is imported to mitochondria interrupts calcium
buffering, electron transport chain, and protein import by blocking import machinery, and
might be a cause of initiating apoptotic pathways by binding to and inactivating Bcl-2
(Boillee et al., 2006). ALS also affects mitochondria structurally, based on observations
of enlarged, disorganized mitochondrial membranes in motor neurons (Dupuis et al.,
2003).
Global gene expression profiling study of SOD1mutant overexpression in mice
showed that the instigation of the disease relates to motor neurons, while advances of the
disease are promoted by astrocytes and microglia (Hedlung et al., 2010). A healthy motor
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neuron consists of up to ~one-meter-long axon, through which transport of cargo takes
place. Healthy motor neurons receive excitatory signals from a glutaminergic neuron that
releases glutamate, which binds to glutamate receptors. A motor neuron is also
surrounded by microglia and astrocytes, which participate in the removal of glutamate
from the synaptic cleft by transporting it though EAA2 transporter into their cell bodies.
It has been observed in SOD1 mutant mouse model that the first event in the ALS
development is in a muscle that loses the synaptic connection between the motor neuron
and a muscle, seen as motor neuron retraction (Pun et al., 2006). This motor neuron
terminal retraction in the early stage of the disease might be due to accumulation of
SOD1 aggregates or neurofilament mis-accumulation, which affects the transport within
the axon, and mitochondrial dysfunction derived from defective mitochondrial transport
into and out of nerve endings.

Activated microglia at the symptomatic stage of the disease, driven by SOD1 released
from the motor neuron, produce toxic factors such as nitric oxide (NO) and tumor
necrosis factor (TNF) alpha that target the same neuron. At the same time, high levels of
glutamate in the synaptic cleft cause constant firing of the motor neuron and calcium
entry trough AMPA receptors (Boillee et al., 2006). This glutamate driven toxicity has
been a target of some drugs like riluzole. Toxic factors like nerve growth factor (NGF)
are also released from the astrocytes, which at this point of a disease progress, lose the
expression of glutamate transporter EAAT2. All of those events lead to caspase
activation and motor neuron apoptosis and muscle atrophy at the end stage.
Motor neuron damage in ALS therefore appears to be caused not only
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autonomously but also by neighboring cells. Microglia activation, and cd16 + monocytes
increased in peripheral blood have been observed in both sporadic and familial ALS. The
abnormally activated monocyte/macrophages correlated to the lipopolysaccharide (LPS)
levels in the peripheral blood (Zhang et al., 2011). Also studies of SOD1 mutant mouse
have shown that expressing SOD1mutation exclusively in the motor neuron and not in
neighboring cells did not induce a disease in some mice.

The fact that neuro-protection can be achieved by just targeting neighboring cells of a
neuron has motivated trials for potential treatment options. Microglia treatment with
minocycline inhibits their activation. TNFalpha antagonist injections or cyclooxygenase 2
(COX2) inhibitor injections showed some promise when it comes to slowing disease
onset (Zhu et al., 2002; Drachmanetal, 2002; West et al., 2004). Another nonneuronal
neighbor target for the disease treatment is the astrocyte. Since expression of EAAT2
glutamate transporter decreases during disease progression, beta-lactam antibiotics that
act as transcriptional inducers of EAAT2 produce improved survival in transgenic SOD1
mice (Rothstein et al., 2005). Also blocking release of glutamate could decrease injury,
which appears to be a major action of riluzole. Although its mechanisms of action are not
fully understood, they also include inactivation of voltage dependent sodium channels or
prevention of glutamate binding to its receptors. In a study of SOD1 ALS mouse model,
the drug extended their survival (Doble, 1996), and riluzole is currently the only FDAapproved drug for ALS.
Muscles as therapeutic targets in ALS
Muscles have been also used as therapy targets because muscles die without
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neuronal stimulation. Increasing mass of muscle by decreasing expression of myostatin,
which slows muscle development, didn’t improve ALS in SOD1 mutant mice (Holzbaur
et al., 2006). Injecting insulin like growth factors IGF-1 caused revival of muscle fibers
and life prolongation of SOD1 mice, therefore opened a possibility of growth factor
therapies (Dobrowolny et al., 2005). Exercising, especially concomitant with IGF1,
showed improvement in ALS transgenic mice (Kaspar et al., 2005).
Growth factors show some benefit in ALS
Infusion of growth factor BDNF through into the brain by ICV or spinal cord
intrathecal injection showed small benefits in patients (Nagano et al., 2005b). In mice
VEGF encoding retrovirus delivery infusion to muscle or ICV injection of VEGF
increased survival (Zheng et al., 2004).

1.2 Mitochondrial genome
Both genetic and sporadic forms of amyotrophic lateral sclerosis present clinically in very
similar ways (Saris et al., 2009, Dupuis et al., 2011, Boillee et al., 2006). This relative
homogeneity of the clinical phenotype of ALS led to a conclusion that there might be few
pathways that are significant in the disease’s evolution. Since some of those pathways
include signaling pathways in peripheral blood cells, it became evident that the peripheral
blood could be used for the gene profiling and become a biomarker for diagnosis of ALS
(Saris et al., 2009; Maes et al., 2007). Another study showed that throughout the course
of ALS damage occurs not only to motor neurons but also to non-neural tissue, including
peripheral lymphocytes (Curti et al., 1996). This damage affects bioenergetics of cells
with mitochondria, being the energy factory, centrally involved in that damage (Dupuis et
11

al., 2011; Heath et al., 2013).
Mitochondria were first described as “chlorophyll bodies” and “cell granules” at the end
of the nineteenth century. Since then, mitochondria were more fully characterized in the
1950’s. Lynn Margulis, who proposed the endosymbiotic theory, formulated their origins
in the early 1970’s. According to this theory, oxidative proteobacteria were symbiotically
incorporated into a prokaryotic or early eukaryotic cell and evolved to become modern
mitochondria.

The endosymbiotic theory is supported by molecular genetics and sequence homology
comparisons between DNA of mitochondria and prokaryotes. The organelle’s ribosome’s
are like prokaryotes (70S) and differ from cytoplasm of eukaryotes (80S). Other
supportive arguments for the endosymbiotic theory include circular mitochondrion
genome and its replication, initiation of RNA translation, and the double membrane of
mitochondria (with the inner mitochondrial membrane being high in cardiolipin content,
which is like bacterial membranes but different from eukaryotic plasma membranes).
Mitochondria within the course of evolution adapted to being inside of the cell by
transferring some of its genome into nucleus, reducing in this way their “supplementary”
genome and energy expenditures (Wallace, 1999).

Mitochondria control many tasks in a cell. They include but are not limited to: initiation
of cell death cascades, regulation of energy production, feedback regulation of Krebs
cycle, maintaining calcium homeostasis, and formation of iron sulfur clusters.
Deregulated of calcium homeostasis, as in the peripheral blood lymphocytes of ALS
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patients, leads to uncoupling of oxidative phosphorylation (Curti et al., 1996).

Figure 1.1. Many functions of mitochondrion. Reeve et al., 2012.
Human mitochondrial genome consists of 16568 base pairs contained on heavy and light
circular DNA strands. The lighter (based on G-C content), inner strand encodes ND6 and
eight tRNA’s; the heavier outer strand encodes 12s and 16s rRNAs, 14 tRNAs, six
subunits of complex I (ND1-5, ND4L), one subunit of complex III (cytochrome b), three
subunits of complex IV (COX I-III), as well as two subunits of complex V (ATP
synthase; ATP6, ATP8). These 13 genes encode proteins of the electron transport chain
(ETC) that are necessary for the capturing of energy in the form of a proton gradient, and
converting it to ATP in a process of oxidative phosphorylation (OXPHOS).

The semiautonomous system of mitochondria relies also on the nuclear genome. The rest
of the proteins, including 74 ETC proteins, enzymes, transcription factors, ribosomal
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proteins, and polymerases are made outside of the mitochondria then imported and
assembled there (Wallace, 1999; Bellance et al., 2009).

Figure 1.2. Mitochondrial genome. Bellance et al., 2009.
The D-loop is a regulatory, non-coding region, with promoters of heavy and light strands
and the origin of replication Heavy strand (OH). According to the ‘strand-asymmetric”
explanation of mtDNA replication, the origin of replication of the light strand (OL) is
located approximately 2/3 of the circumference from OH. The replication cycle is about
two hours long and starts with the replication of the heavy chain proceeding
counterclockwise.

A single mitochondrial polycistronic mRNA encodes several different
polypeptide chains (Bellance et al., 2009). The mitochondrial genome is unique in many
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aspects. It not only has a distinctive code for translating DNA and replicates
independently from the nuclear genome, but also its RNA is capable of enzymatic
activity and of joining two transcripts together with so-called trans-splicing (Williams,
2002). Human mitochondrial (mt) genome was thought to be mainly maternally inherited.
This was attributed to the fact that paternal mitochondria present in the tail of sperm, do
not enter an oocyte, and if they do, they are overcome by abundant maternal mtDNA and
damaged by reactive oxygen species (ROS) (Luo et al., 2013; Williams, 2002). Despite
this general belief, it has been observed in rare situations that mitochondria from the
father can be passed to the offspring in humans. A patient of Schwartz and Vissing with
trademarks of mitochondrial myopathy, ragged-red muscle fibers and exercise exertion, is
one example of mitochondrial paternal inheritance. The detailed sequencing analysis of
the mitochondrial genome in the quadriceps muscle of this patient has shown, that the
mutation in the ND2 gene was derived from the father. Interestingly, the mutation was
not present in circulating lymphocytes and that is consistent with the fact that
mitochondrial mutations are often localized to a specific tissue (Schwartz and Vissing,
2002; Williams, 2002).

Mitochondrial DNA has a larger mutation rate than does nuclear DNA (Wallace, 1999).
The mutation frequency increases with age even in a healthy person, and is accelerated in
degenerative diseases (Williams, 2002). The mutated state (heteroplasmy) can be
transferred to the somatic cell progeny and be a cause of diminishing bioenergetic
capacity of a cell by a process known as “Muller’s ratchet” that describes increasing
mutational burden associated with non-sexual reproduction of DNA. It follows that the
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tissues affected the most by mitochondrial mutations, are the ones with high-energy
demands like neurons, cardiac muscle and skeletal muscle. This energy and disease
correlation was observed in many studies. For example, the mitochondrial DNA study by
Keeney et al. showed increased mtDNA point mutations in spinal cord neurons of
patients with ALS as well as decreased cytochrome oxidase activity, which is an
important part of ETC. Also, a Parkinson's disease study showed increased abundances of
mtDNA deletions that included cytochrome oxidase and complex I of ETC (Bender et al.
2006).
The cell energy production relies on the interaction of three processes that take place in
mitochondria: oxidative phosphorylation, production of the radical oxygen species and
apoptosis (Wallace, 1999). The interruption of this state of equilibrium by, for example,
cellular mutations, leads to a disease. The energy currency of the cell, ATP is produced in
mitochondrial ETC in the process of oxidative phosphorylation. The ETC consists of five
complexes; NADH dehydrogenase (complex I; 7mt DNA {ND1-6, ND4L}, 40 nDNA),
succinate dehydrogenase (complex II; 0mtDNA, 4nDNA), ubiquinol cytochrome C
oxidoreductase (complex III; 1mtDNA{cytochrome b}, 10 nDNA), cytochrome C
oxidase (complex IV; 3mt DNA {COX I-III}, 10 nDNA) and ATP synthase (complex V;
2mt DNA {ATP6, ATP8}, 15 nDNA).
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Figure 1.3. Inner membrane Electron Transport Chain of mitochondria. Bellance et al.,
2009.
This chain of proteins oxidizes NADH and FADH2 that were produced in the Krebs
cycle from the pyruvate from glycolysis. NADH and FADH2 enter the ETC at the
complexes I and II respectively and electrons released in this process of oxidation are
transferred to coenzyme Q. ComplexIII passes these electrons to cytochrome c, and
cytochrome c to complex IV. Oxygen consumption takes place in complex IV where the
O2 is “sucked up” by heme3 and reduced to H20. Complex V of ETC of mitochondria
uses electrochemical proton gradient created by ETC (H+ moved to inter-membrane
space) to generate ATP from ADP and phosphate. ETC although often described as
consisting of single complexes is in reality an assembly of supercomplexes so called
“respirasomes” that is few subunits of a specific complex bound to each other. The ratio
of these complexes varies for different tissues. Respirasomes minimize diffusion
distances of substrates and electron leakage (Schägger and Pfeiffer, 2001) and the
leakage in ETC can cause oxidative damage to many cellular components including
17

cellular and mitochondrial membranes as well as it can inactivate the energy production
through oxidative phosphorylation.

Figure 1.4. Reactive Oxygen and Nitrogen Species. Bellance et al., 2009.

Oxygen molecules that are abundant in mitochondrial matrix can accept free electrons
that leave complex I and complex III of the ETC, yielding superoxide anion, that under
normal conditions is converted to hydrogen peroxide by Mn/Mg superoxide dismutase
(SOD-2). Mitochondria have high levels of reduced glutathione (GSH) that is a
component of glutathione peroxidase and catalase can convert hydrogen peroxide to
water. If that process of superoxide removal is deregulated it leads to generation of
reactive oxygen species (ROS) and reactive nitrogen species (RNS) and causes oxidative
and nitrosative damage of DNA, proteins and lipids.
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Increased ROS can also cause opening of mitochondrial permeability transition
pore (mtPTP), which leads to the initiation of apoptosis. The cascades of events follows;
discharge of the electrochemical gradient of mitochondrial membrane, inflation of inner
membrane, release of cytochrome c, activation of caspases and apoptosis. This interplay
between oxidative phosphorylation, reactive oxygen species, apoptosis taking place in
mitochondria is fundamental in bioenergetics of the cell.

1.3 Induced Pluripotent Stem Cells (iPSCs)

One of the main concerns of neurodegenerative studies is the amount of tissue available
for research. Many studies utilize postmortem samples from autopsies (Payne et al.,
2014; Gage et al. 2013; Wang, 2006) with limited amount of nucleic acid for analysis
from samples that are also at the final stage of the diseases. Also, the animal models
created for studies are genetic, which do not necessarily reflect the most commonly
occurring (~95%) sporadic forms of human ALS. This pursuit of plausible solutions to
overcome these limitations has directed attention to induced pluripotent stems cells
(iPSCs), induced neuronal phenotypes (iN), and somatic cell neural transfer (NT)
(Wernig et al., 2013; Mertens et al. 2013; Staerk et al. 2010; Wang et al. 2013), and has
inspired the development of disease models which could potentially lead to the advances
in crucial treatment options for neurodegenerative diseases including ALS. The
reprogrammed cells from genetically unique patients would allow studies of specific
pathways in motor neurons even ahead of a disease manifestation, and would make for a
plausible design of personalized pharmacological treatment (Gage et al., 2013). For
therapy, iPSC’s could be differentiated to motor neurons, which can be delivered back to
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the patient (Oakely et al., 2013). The reports of successful autologous transplantation of
stem cells from bone marrow to ALS patients have been seen in studies (Feng et al.,
2012).
Among the somatic cell types that have been effectively reprogrammed into iPSC
are mononuclear cells (MNC) (Dupuis et al., 2013). These blood cells, isolated from
either the umbilical cord (CB) or adult peripheral blood (PMNC), offer several
advantages among which is their low number of somatic mutations as a result of their
short life span, compared to skin fibroblasts (Oakely et al., 2013; Feng et al., 2012) which
are also used for iPSC generation. The other advantage is their short culture time as well
as accessibility (Dupui et al., 2013). Originally human iPSC were derived using a
retroviral vectors, however, the questionable safety of injecting a retro or lento-virus into
humans and the resulting mutations they created (Yu et al., 2009) redirected attention of
researchers to recombinant proteins usage. This approach, though plausible, was very
inefficient (Dupuis et al., 2011) therefore a method of using non-integrating or excisable
vectors and transduction of the reprogramming factors was developed (Dupuis et al.,
2013; Jaenish et al., 2013; Yu et al., 2009).

The other experimental parameter that affects the quality of iPSC is the number of
reprogramming factors and donor cells (Jaenish et al. 2013). Dupuis et al. reported a
successful single plasmid transfection of pEB-C5 plasmid containing EBNA1/OriP OriP
sequences of the Epstein-Barr with five reprogramming factors Oct4, Sox2, Klf4, c-Myc
and Lin28. The plasmid was not integrated into the genome so it is much safer than using
a retrovirus, and preferentially expanded erythroblasts over T lymphocytes before
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reprogramming, since T lymphocytes have high number of somatic VDJ rearrangements
(Dupuis et al., 2011; Yu et al., 2009). To improve reprogramming efficiency of PMNC
sodium butyrate can be added to the media (Chou et al., 2011).
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Chapter 2:
2.1 Materials and Methods
Tissue Culture
Peripheral blood of two ALS and one non-ALS healthy control (CTL) patients was
collected at the Parkinson’s and Movement Disorder’s Center Medical College of
Virginia according to VCU IRB-approved protocol. Within four hours after blood
collection, mononuclear cells (MNC) were separated from other blood cells using FicollPaque Premium density-based centrifugation. In this method MNC, being of lower
density, stay in the top layer above Ficoll which is a hydrophilic polysaccharide and the
separation agent for this method. QIAzol Lysis Reagent (Qiagen) was used to remove
any remaining red blood cells. The peripheral blood MNC (PMNC) was stored at -80
degrees Celsius.
The generation of human induced pluripotent stem cells from PMNC was attempted by
following the protocol of Dowey et al., 2012.
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Figure 2.1. Generation of integration free human iPSC protocol. Dowey et al., 2012.
MNC were isolated and expanded in MNC medium for 14 days. This medium was serum
free with cytokines that would favor erythroblasts over lymphocytes development. On
day 14 MNC were transfected with episomal plasmid pEB C5, expressing OriP
sequences of the EpsteinBarr and five reprogramming transgenes Oct4, Sox2, Klf4,
c-Myc and Lin28. The 4D-Nucleofector Core Unit and X Unit (Lonza) were used for
reprogramming. This event started the generation of iPSCs. The cells were then
transferred to feeder-coated plates containing mouse embryonic fibroblasts (MEF) and
the medium was switched from MNC to MEF medium with antibiotic antimycotic and lglutamine. On the third day after transfection, MNC medium was replaced with
embryonic stem cell (ESC) medium. The iPSCs colonies start multiplying on day 14.

23

Figure 2.2. An image of a commercial MNC (All Cells) that were transfected in previous
experiments by another research group member. Image is of MNC two days after
transfection stained with a GFP green fluorescent protein (GFP) plasmid. It was a
positive control for the transfection process.

.
Figure 2.3. An image of a commercial MNC (All Cells) that were transfected in previous
experiments by another research group member. Image is of MNC two days after
transfection stained with just PBS as a negative control.
Two weeks after the transfection, cells can be stained with TRA-1-60 antibody to confirm
the identity of successfully reprogrammed iPSCs colonies. Unfortunately, in my
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experiment after morphological assessment of the cell culture, no iPSC were identified,
therefore TRA-1-60 staining was not performed.

Figure 2.4. An image of a commercial MNC (All Cells) that were transfected in previous
experiments by another research group member. Image is of the same MNC cell line as in
Figure 2.2 and Figure 2.3 fourteen days after transfection with plasmids. It has been
stained with an antibody to TRA-1-60, which is an early marker of pluripotency.
RNA and DNA extractions
The extraction process is used to separate DNA and RNA from biological samples using
chemical and physical methods. The intricacy of the RNA extraction lies in the
realization of omnipresence of RNAases that degrade RNA and making a great effort to
eliminate them.
In this experiment RNA and DNA were extracted from PBMC samples using an AllPrep
DNA/RNA Mini Kit (Qiagen), which allowed simultaneous purification of genomic
DNA and total RNA. The first step of DNA/RNA extraction was disruption of plasma
membrane using RLT buffer containing guanidine thiocyanate followed by samples’
homogenization to reduce the viscosity of the lysate. This would allow for better binding
of DNA and RNA to mini spin columns. The DNA was separated from RNA using
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AllPrepDNA mini spin column to which DNA bound. Consequently, ethanol was added
to the eluted RNA to precipitate it. The next steps for RNA and DNA extraction consisted
of adding RW1 buffer with ethanol to the RNA column and AW1 buffer with
Guanidinium hydrochloride to DNA column, then washing them.

Following the DNA and RNA extraction, both nucleic acids were subjected to quality
control (QC) using Nanodrop 2000c spectrophotometer (Thermo Scientific) for DNA and
Experion Automated Electrophoresis System (Bio-Rad) for RNA.
Experion RNA StdSens analysis kit was used to determine total RNA concentration and
establish its integrity using RNA quality indicator (RQI) number with a scale 1-10, 10
being the highest. After the chip preparation, which included adding gel stain containing
fluorescent dye and sieving matrix, the chip was inserted into the electrophoresis station
with voltage sensitive electrodes. Charged RNA fragments were separated on their size
basis (virtual gel matrix), and the fluorescent dye penetrated the fragments. Following the
detection by a photodiode of fluorescence of the laser-exciting sample fragments, the
software created fluorescence intensity versus time plots (electropherogram). The total
RNA sample was separated into two peaks that represented 18S and 28S ribosomal RNA
(rRNA) and the software compared the area under the electropherogram to calculate total
concentration of the sample. RNA was then reversely transcribed to cDNA using iScript
(Bio-Rad) using GeneAmp PCR system 9700 (Applied Biosystems).

Nanodrop 2000c spectrophotometer (Thermo Scientific) was used for quality control
(QC) of DNA, which measured the intensity of light transmitted through the sample. The
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absorbance at a given wavelength was then calculated according to the equation:

Absorbance= -log [Intensity of sample/Intensity of blank]

The Beer-Lambert equation was used to correlate the calculated absorbance with
concentration:
A=ε*b*c

Where A is the absorbance represented in absorbance units (A), ε is the extinction
coefficient liter/mol*cm, b is the length of solution the light passes through in cm, and c
is the analyte concentration in moles/liter or molarity (M).
The reference buffer used in this experiment was Tris (hydroxymethyl) aminomethane Ethylenediaminetetraacetic acid (Tris- EDTA that is TE) buffer in which DNA was
dissolved. TE solubilizes DNA while protecting it from degradation. To assess the purity
of DNA the ratio of absorbances at 260nm/280nm was calculated. DNA absorbs UV light
at 260 and 280 nanometers and pure DNA has a ratio of 1.8. A lower ratio may indicate
presence of protein, phenol or other contaminants because aromatic proteins absorb UV
light at 280 nm. The secondary measurement of 260nm/230nm additionally assesses
nucleic acid purity. A ratio of 260/230 lower than 1.8-2.2 indicates the presence of
copurified contaminants.

Selection of Genes of interests and Quantitative PCR
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Real time polymerase chain reaction (qPCR) is a technique that amplifies and
simultaneously quantifies a targeted molecule utilizing the physiochemical properties of
nucleic acids and DNA polymerase. It provides an amplification plot based on the
changes in fluorescence, which is proportional to the amount of the target. QPCR is also
a common technique for studying gene expression of neurological diseases. The
advantage of this method is the sensitivity of the measurement to small amounts of
mRNA. However, this technique entails the necessity of normalization to housekeeping
genes that are transcribed continuously at a constant rate, which guarantees a stable level
of mRNA regardless of the experimental condition. Geometric means need to be used
because the absolute expression levels of reference genes can vary widely, and geometric
means (as opposed to typical arithmetic means) distribute this difference. GeNorm is
used to find the least variable reference genes in the cells of interest, independently of
their absolute expression levels. Also, cell types and disease progression, and their
amount, would be comparable to the analyzed genes. According to Penna et al. (2011)
and their GeNorm and NormFinder analysis of gene stability, the most stable reference
gene in postmortem brain was CYC1, however; they recommended a combination of
reference genes. Following the experience from our research group (Keeney et. al., 2010)
the housekeeping genes chosen for normalization were TOP1 (encodes DNA
topoisomerase type I which enzymatically breaks and rejoins a single strand of DNA),
GAPDH (encodes glyceraldehyde-3-phosphate dehydrogenase, an enzyme that catalyzes
the sixth step of glycolysis, which has been extensively used in different studies as a
reference gene (Penna et al. 2011), YWHAH (tyrosine 3-monooxygenase/tryptophan 5monooxygenase activation protein, which encodes a 14-3-3 family of proteins that
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mediate signal transduction in cells by binding to phosphoserine containing proteins) and
CYC1 (encodes cytochrome C1, mitochondrial heme protein). The normalization factor
for mtDNA was a geometric mean of GAPDH and YWHAH for mtDNA and TOP1 and
CYC1 for mt cDNA. 1
It was crucial to establish suitable candidates for the gene analysis. According to Keeney
et al. (2011), the mitochondrial genes encoding respiratory proteins ND4 and COX III are
frequently deleted in cervical spinal cord major arc ALS patients and ND2 is also deleted
but less frequently. The 12s rRNA gene product is involved in the assembly of proteins
within cells present only in mitochondria.
QPCR was performed with human mtDNA copy number standards (for mtDNA qPCR)
or human fetal brain cDNA (for mt cDNA qPCR) using iQ Multiplex Power Mix in a
CFX-96 Real-Time PCR instrument iCycler with aniQ5 detection system (BioRad,
Hercules, CA). MtDNA genes ND2, ND4, COX III, and 12s rRNA were measured using
dyes (FAM- ND2, Texas Red- ND4, TET- COX III, Quasar- 12s rRNA) as well as sense
and antisense primers. Each sample and standard was quadrupled. The cycling protocol
consisted of activation at 95°C for 5 min followed by 50 cycles of: 95°C melting for 10
seconds (allowing for the separation of the double chain), and 50°C for 1 minute
(allowing for the binding of the primers with the DNA template). Data was analyzed
using the iQ5 software. QPCRs for the reference genes GAPDH, YWHAH, TOP1, CYC1
were performed individually using EvaGreen® Supermix (BioRad) and primers designed
for PCR. The standard curves generated showed similar efficiencies of the qPCR runs.

29

2.2 Results
Tissue culture
In this study another research group member cultured MNC from ALS patients. I cultured
MNC from a CTL subject. My two additional MNC cultures from ALS patients were
contaminated during the course of the study, and the efforts of reprogramming MNC to
iPSCs from the CTL subjects were unsuccessful for the reasons addressed in discussion.
After morphological assessment of my cell culture, no iPSC were identified; therefore
TRA-1-60 staining was not performed.

RNA and DNA Quality Control
For ALS and control PBMC samples the quality indicator (RQI) numbers were between
9.8 -10. For the CTL sample before culturing, however (sample number 9), there was a
critical anomaly error, which could have been due to some contamination. It could not
have been a result of RNA concentration, which was not the lowest one (62 ng/ul). The
RNA concentrations ranged between 38.25 ng/ul for the ALS sample I before culturing,
and 257.39 ng/ul for the ALS sample II after culturing (See Table 2.1).

W ell ID

Samp le Na me

RNA Area

La dd er

83 6 .1 4

160

1

AL S4 6 I

19 9 .8 9

38. 25

0. 02

10

G reen

2

ALS 46 # 1

8 62. 8

165. 1

1. 88

9. 8

G reen

3

A LS 4 6# 2

77 4 .7 7

148. 26

1. 73

9. 9

G reen

4

A LS 4 6# 3

83 1 .1 4

159. 04

1. 96

10

G reen

5

A LS 4 8 II

21 7 .8 7

41. 69

2. 05

10

G reen

6

A LS 4 8# 1

80 1 .0 3

153. 28

1. 64

9

G reen

7

A LS 4 8# 2

68 7 .3 2

131. 52

2. 07

10

G reen

8

A LS 4 8# 3

13 45. 07

257. 39

1. 85

9. 9

G reen

9

CT L 4 7 I

32 4 .1 2

62. 02

2. 25

N/ A

10

C TL 47# 1

30 3 .0 5

57. 99

0. 06

10

L

R NA C onc ent ra tion (ng/ !l)

R at io [ 28S /1 8S]

RQ I R Q I C lass ificat ion

R Q I Alert

Critical A nom aly
G reen

Table 2.1. Quality Control results of RNA using Experion Automated Electrophoresis
System (Bio-Rad).
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The measured 260/280 ratios for the DNA samples were within 1.86-1.89 range, which
confirmed their purity from aromatic proteins. However, there might have been some
other contaminant in the CTL sample before culturing (sample number 9), because the
ratio 260/230 was much lower than the purity range that is 0.63.
The DNA concentrations varied between 128.5 ng/ul for the sample 10 (CLT after
culturing) and 311.4 ng/ul for the sample 8 (ALS 48 after culturing) (See Table 2.2)

# Sam ple ID User na me

Dat e a n d Tim e

Nucle ic Acid Co nc. Unit A260 A280 260/280 260/230 Sa m p le Type Fa ctor

1 1 ALS 46 I Adm inis trator 5/21/2014 11:35:56 AM

270

ng/!l 5.4

2 2 ALS 46 #1 Adm inis trator 5/21/2014 11:37:36 AM

250

ng/!l

1.86

2.03

DNA

50

2.674 1.87

2.08

DNA

50

3 3 ALS 46 #2 Adm inis trator 5/21/2014 11:38:34 AM

231.4

ng/!l 4.627 2.453 1.89

1.83

DNA

50

4 4 ALS 46 #3 Adm inis trator 5/21/2014 11:39:36 AM

223.5

ng/!l 4.471 2.385 1.87

2.04

DNA

50

5 5 ALS 48 I Adm inis trator 5/21/2014 11:40:39 AM

197.8

ng/!l 3.955 2.121 1.86

1.4

DNA

50

6 6 ALS 48 #1 Adm inis trator 5/21/2014 11:41:45 AM

295

ng/!l 5.899 3.155 1.87

2.09

DNA

50

7 7 ALS 48 #2 Adm inis trator 5/21/2014 11:42:36 AM
8 8 ALS 48 #3 Adm inis trator 5/21/2014 11:43:37 AM

254.9
311.4

ng/!l 5.098 2.73 1.87
ng/!l 6.228 3.325 1.87

1.84
1.96

DNA
DNA

50
50

9 9 C TL 47 I I Adm inis trator 5/21/2014 11:44:45 AM

242.5

ng/!l 4.85 2.601 1.86

0.63

DNA

50

10 10 C TL 47 #1 Adm inis trator 5/21/2014 11:46:01 AM

128.5

ng/!l 2.57 1.385 1.86

1.54

DNA

50

5

2.9

Table 2.2. Quality Control results of DNA using Nanodrop 2000c spectrophotometer
(Thermo Scientific).

Mitochondrial cDNA/ RNA quantification
The results of qPCR were normalized to two housekeeping genes CYC1 and TOP1 by
dividing SQ means by the geometric mean of two housekeeping genes. Mt cDNA of
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analyzed genes ND2, ND4, COX III and 12s rRNA showed higher gene expression in
ALS MNC before culturing compared to CTL before culturing for all genes.
Specifically, ND2 expression was increased by 2.4 for ALS comparing to CTL which
was increased by 1.6 and COX III expression increased by 2.6 for ALS versus CTL
increase of 2. There was no apparent increase of gene expression for 125s rRNA (1.1 for
ALS and 0.8 for CTL) and ND4 (1.05 for ALS .95 for CTL)(Figures 2.5-2.8).

Figure 2.5. ND2 gene expression in ALS versus CTL MNC before and after culturing.

Figure 2.6. COX III gene expression in ALS versus CTL MNC before and after
culturing.

Figure 2.7. 12s rRNA gene expression in ALS versus CTL MNC before and after
culturing.
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Figure 2.8. ND4 gene expression in ALS versus CTL MNC before and after culturing.
After culturing, ALS and CTL gene expression was decreased for all genes in comparison
to ALS and CTL gene expression before culturing. ALS gene expression was comparable
to CTL gene expression for all genes.
mtDNA copy numbers
The results of qPCR were normalized to two housekeeping genes GAPDH and YAHWZ
by dividing SQ means by the geometric mean of two housekeeping genes. Mitochondrial
DNA copy numbers of analyzed genes ND2, ND4, COXIII and 12s rRNA were increased
in MNC after culturing compared to copy numbers before culturing for all ALS and CTL
samples. There was an increase in copy numbers for the respiratory genes ND2, ND4,
COX III which was ~1200000 for ALS compared to ~1000000 copy numbers of CTL.
There was no apparent difference in copy numbers of 12s rRNA expression of ALS
compared to CTL. Copy numbers for CTL were higher for all genes after culturing
comparing to before culturing (Figures 2.9 – 2.12).
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ND2 copy Numbers. Normalized

Figure 2.9. ND2 mtDNA copy numbers in ALS versus CTL MNC before and after
culturing.

COXIII copy Numbers. Normalized

Figure 2.10. COX III mtDNA copy numbers in ALS versus CTL MNC before and after
culturing.

12s rRNA copy Numbers. Normalized

Figure 2.11. 12s rRNA mtDNA copy numbers in ALS versus CTL MNC before and after
culturing.
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ND4copy Numbers. Normalized

Figure 2.12. ND4 mtDNA copy numbers in ALS versus CTL MNC before and after
culturing.

2.3 Discussion

ALS, despite tremendous research efforts and palliative therapy advances, remains a
lethal motor neuron disease. The etiology of ALS, most of which occurs sporadically, is
still unknown and the endeavor dedicated to its characterization and finding consequent
treatment options, led scientists to intensive research of cell components. Given the
heterogeneity of sporadic ALS clinically, there may be different etiologies and
mechanisms responsible for progression. Free radicals’ formation, oxidative stress,
autophagy, and mitochondrial dysfunction lead to energy deficiencies of cells in animal
models (Dupuis et al., 2011; Wallace et al. 1999., Curti et al., 1996; Oakley et al. 2013).
Each of these processes, singly or in combination, may underlie the origin(s) and
progression of ALS.
Extensive studies have tried to find genes responsible for ALS. In this search, few
nuclear genes have been identified that are linked to the disease. Mutation in SOD1 gene
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resulting in toxic aggregates causes not only impairment for proteasomes and cellular
chaperones but SOD1 transport and accumulation in mitochondria may play a negative
affect on calcium channels, electron transport chain and may prematurely trigger
apoptosis. Other cellular aggregates like 43-kDa (TDP-43), fused sarcoma protein (FUS)
and neurofilaments have been also observed as characteristic of a disease progression
(Kwiatkowski et al., 2009; Dupuis et al., 2011; Garcia et al., 2006). Not only the motor
neuron itself but also its neighbors are central players in ALS.
Microglia and astrocytes can also release toxic factors that contribute to the
disease development. Activation of microglia leads to release of glutamate that resides
longer in the synaptic cleft because it can not be removed by glutamate transporters
(which are lost from astrocytes during ALS progression). This leads to perpetual
activation of the motor neuron and calcium influx. 2
It has been observed that ALS not only affects the nervous system but also has a
holistic impact on the body and all its cells. In particular, peripheral mononuclear cells
may be taken into consideration as potential screening candidates for detecting the
disease at early stages (Zhang et al., 2011). Looking at bioenergetic deficiency of a cell
and mitochondrial gene expression could lead to ALS characterization at different stages
of its progress. Also peripheral blood MNC can be used to develop induced pluripotent
stem cells (iPSC) leading to potential treatment options of ALS and many other
degenerative diseases, such as Parkinson’s and Alzheimer’s disease.
In this work we tried to induce PSC from mononuclear cells taken from the
peripheral blood of patients with ALS and healthy control. The protocol for MNC
expansion was used according to Dowey et al., 2012. According to this protocol MNC
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were isolated and expanded in serum free MNC medium with cytokines for 14 days. On
day 14 MNC were transfected with episomal plasmid containing reprogramming
transgenes Oct4, Sox2, Klf4, c-Myc and Lin28, which started the generation of iPSCs.
Consequently, transfected MNC expanded in different media favoring development of
iPSC.
Starting with three samples, peripheral MNC from two ALS patients and one
control CTL, the two ALS samples have been contaminated during the course of MNC
expansion. Working with a tissue culture demands a sterile technique. This technique
involves special training and different cells have different susceptibility to contamination.
I received training on SY5Y cells, which is human neuroblastoma cell line. Working with
human MNC samples requires more precise and finer technique comparing to SY5Y
because of the amounts of cells and media contained in wells comparing to flasks of
SY5Y cells. The factors mentioned above plus multiple steps, elaborate, every day
preparation of different media for MNC expansion may have contributed to the
contamination of cells. The SY5Y cell line had only one type of media prepared in
advance limiting the possibility of contamination. In the course of learning the sterile
technique, the CTL cell line was not contaminated. Despite the efforts of expansion and
the cell culture, I did not detect any iPSCs. The unsuccessful reprogramming of MNC to
iPSCs could be attributed to many factors. Peripheral blood monocytes have lower
reprogramming efficiency than cord blood (Chou et al., 2011). The cell counts of my
original CTL sample were low at the beginning of the expansion, and the colony was
growing poorly, which might be an indicator of sample contamination, especially after
considering the quality control index CQ of RNA and DNA for that sample. Additionally,
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nucleofection, which transfers substrates (in this case plasmid) into the cell by applying
an external electric field, causes excessive cell death and can be responsible for low
transfection efficiency. Many of the cells die at this point before colonies can develop.

For future studies to enhance reprogramming efficiency, the starting MNC cell count
should be chosen to be higher as compared to Dowey et al. Few adjustments could have
been made to my experiment to obtain better results. Being able to ensure the quality of
the blood samples before the cell expansion could have been an advantage since the
growth of the colonies and quality of DNA and RNA might have been affected by the
quality of blood MNC before culturing. No staining experiment was performed to
exclude possibility of omitting the iPSC colonies during the transfer to different media.
There was also no absolute identification of the colonies after iPSC expansion only the
morphological assessment. After the transfection the colonies were picked manually
under the microscope, which could have contributed to the excluding iPSC cell lines. The
iPSC colonies might have been lost during the course of expansion because some of them
did not adhere to the gel.

The significant drawback of my study was the limited sample numbers. Working with
more samples could be very beneficial, as it would identify the outliers and minimize the
experimental error. Also, having just one control sample with lower quality of DNA
could have misled the conclusions.
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The qPCR mitochondrial gene expression study showed that mitochondrial cDNA
of analyzed genes ND2, ND4, COX III and 12s rRNA was higher in ALS MNC before
culturing compared to CTL before culturing for all genes. This increase in cDNA might
be an indicator of increased protein numbers in ALS patients as a response to higher
energy demands. An increase was observed in mitochondrial DNA copy numbers of
analyzed genes ND2, ND4, COX III and 12s rRNA in MNC after culturing compared to
copy numbers before culturing for all ALS and CTL samples. This is opposite to what
occurred in the cDNA samples. There was a decrease in cDNA gene expression for both
ALS and CTL after culturing. Therefore mtDNA copy numbers in genomic DNA
increased slightly after culturing, but cDNA consistently decreased after culturing. This
discrepancy between mtDNA copy number and mtRNA (as cDNA) expression might be
contributed to the fact that we did not determine appropriate reference genes for the MNC
after culturing which is a shortcoming of this study. GeNorm analysis would be necessary
because monocytes after culturing are in principle different cells then before culturing.
Looking at the graphs, the proportional decrease in gene expression after culturing
appears greater in ALS compared to CTL, whereas mtDNA gene copy numbers increase
more in CTL than in ALS. Therefore ALS samples appear more impaired than CTL in
increasing their mtDNA copy numbers and lose more mtDNA gene expression.
There was no apparent difference in copy numbers of 12s rRNA genes of ALS
compared to CTL which could be attributed to the fact that 12s rRNA has a separate
transcriptional promoter from the genes encoding respiratory proteins ND2, ND4, and
COX III which is not affected in the course of ALS. Only COXIII and ND4 had
increased expression in ALS patients in comparison to CTL. Although mtDNA copy
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numbers were not markedly reduced in ALS MNC blood compared to CTL MNC, it
supports results of Keeney et al. where mtDNA gene copy numbers in ALS spinal motor
neurons decreased in ALS patients. Overall, these results implicate deregulated
mitochondrial bioenergetics at a systems level as a characteristic of ALS.
For future experiments it would be beneficial to see and compare the
demographics of patients with ALS to draw accurate conclusions and make connections
between age, sex and familial history of ALS. It would be also valuable to carry out a
study on patients’ family members, and compare their mitochondrial gene expression.
Periodical screening of MNC mitochondrial gene expression of the same patient would
contribute to understanding of the processes that guide ALS progression and would
reveal its correlations to mitochondrial bioenergetics. If that is successful then peripheral
mononuclear cells may be considered as potential screening candidates for detecting the
disease at early stages. It would be also beneficial to look at potential cross talk between
the MNC and other blood components by testing for inflammatory cytokines, growth
factors and necrosis factors, which could also change during the disease’s course and
could be indicators of disease progression and could aid ALS diagnosis.

2.4 Conclusion

The motivation for this thesis has been an examination of was to examine the
mitochondrial genome in the mononuclear cells of amyotrophic lateral sclerosis (ALS)
patients. The deviations in the gene expression could contribute to the mitochondrial
energy deficiency and be an underlying cause of this lethal neurological disorder of
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motor neurons. The mitochondrial DNA genes examined were ND2, ND4, COXIII and
12s rRNA. The qPCR mitochondrial gene expression study showed that mitochondrial
DNA copy numbers in genomic DNA increased slightly after culturing, but cDNA
consistently decreased after culturing. The results implicate deregulated mitochondrial
bioenergetics as a characteristic of ALS. Future studies with reevaluated choice of
housekeeping genes and potential temporal study of mitochondrial genome could lead to
future elucidating the origins of ALS. The development of a disease model from induced
pluripotent stems cells (iPSCs) have been explored as a potential treatment option for
neurodegenerative diseases including amyotrophic lateral sclerosis. The reprogramming
of mononuclear cells (MNC) to iPSCs would allow for a plausible design of personalized
pharmacological treatment, as iPSCs differentiated to motor neurons, which could be
delivered to the same patient and uniquely target the disease. The technique of
transfection of mononuclear cells with non-integrating episomal plasmid has a great
potential for successful reprogramming of mononuclear cells into iPSC however for
future studies it can be improved by increasing the number of MNC before nucleofection.
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